Tevogen Bio Holdings Inc (TVGNW) News

Form 4 - Statement of changes in beneficial ownership of securities

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday...

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”...

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”...

Form 8-K/A - Current report: [Amend]

Tevogen Bio Reports First Quarter 2024 Financial Results

Confirms liability elimination of $94.9 million and discloses $11.3 million of net incomeReports net cash used...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

WARREN, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”...

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path...

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform...

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet...

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and...

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a...